Pfizer Inc. (NYSE:PFE) Shares Sold by NBC Securities Inc.

NBC Securities Inc. lowered its position in Pfizer Inc. (NYSE:PFE) by 2.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 60,849 shares of the biopharmaceutical company’s stock after selling 1,630 shares during the period. NBC Securities Inc.’s holdings in Pfizer were worth $1,688,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of PFE. Rathbones Group PLC raised its position in shares of Pfizer by 29.1% during the 3rd quarter. Rathbones Group PLC now owns 635,548 shares of the biopharmaceutical company’s stock worth $21,081,000 after purchasing an additional 143,299 shares during the last quarter. V Square Quantitative Management LLC raised its position in shares of Pfizer by 1,394.1% during the 3rd quarter. V Square Quantitative Management LLC now owns 5,827 shares of the biopharmaceutical company’s stock worth $193,000 after purchasing an additional 5,437 shares during the last quarter. Provence Wealth Management Group raised its position in shares of Pfizer by 15.2% during the 3rd quarter. Provence Wealth Management Group now owns 8,659 shares of the biopharmaceutical company’s stock worth $287,000 after purchasing an additional 1,143 shares during the last quarter. Estabrook Capital Management raised its position in shares of Pfizer by 8.5% during the 3rd quarter. Estabrook Capital Management now owns 333,217 shares of the biopharmaceutical company’s stock worth $11,053,000 after purchasing an additional 26,208 shares during the last quarter. Finally, Brandes Investment Partners LP raised its position in shares of Pfizer by 4.2% during the 3rd quarter. Brandes Investment Partners LP now owns 2,957,423 shares of the biopharmaceutical company’s stock worth $98,098,000 after purchasing an additional 119,009 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

Pfizer stock opened at $27.41 on Thursday. The firm has a 50 day simple moving average of $27.61 and a 200-day simple moving average of $27.73. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $39.87. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The firm’s quarterly revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the company posted $1.23 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 14th. Investors of record on Friday, May 10th were given a dividend of $0.42 per share. The ex-dividend date of this dividend was Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.13%. Pfizer’s payout ratio is currently -2,799.53%.

Wall Street Analyst Weigh In

PFE has been the subject of several research analyst reports. Morgan Stanley upped their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday. Guggenheim assumed coverage on shares of Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Ten analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $35.86.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.